The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era
Open accessAbstract
Tuberculosis is the number one cause of death from infectious disease globally and drug-resistant forms of the disease are a major risk to global health security. On the occasion of World Tuberculosis Day (March 24, 2018), we provide an up-to-date review of the status of the tuberculosis epidemic, recommended diagnostics, drug treatments and vaccines, progress in delivery of care and prevention, progress in research and development, and actions needed to accelerate progress. This Review is presented in the context of the UN Sustainable Development Goals and WHO's End TB Strategy, which share the aim of ending the global tuberculosis epidemic. In 2016, globally there were an estimated 10·4 million new cases of tuberculosis, and 600 000 new cases with resistance to rifampicin (the most powerful first-line drug). All countries and age groups are affected by tuberculosis, but most cases (90%) in 2016 were in adults, and almost two-thirds were accounted for by seven countries: India, Indonesia, China, Philippines, Pakistan, South Africa, and Nigeria. The sex ratio (male to female) was 1·9 and 10% of patients with newly diagnosed tuberculosis were also HIV-positive. There were 1·7 million deaths from tuberculosis in 2016, including 0·4 million deaths among people co-infected with HIV (officially classified as deaths caused by HIV/AIDS). Progress in care and prevention means that the global mortality rate (deaths per 100 000 people per year) is decreasing by 3·4% per year and incidence (new cases per 100 000 people per year) is decreasing by 1·9% per year. From 2000 to 2016, the annual global number of tuberculosis deaths decreased by 24% and the mortality rate declined by 37%. Worldwide, an estimated 53 million deaths were averted through successful treatment. Nonetheless, major gaps in care and prevention remain. For example, the 6·3 million new cases of tuberculosis reported globally in 2016 represented only 61% of the estimated incidence; only one in five of the estimated number of people with drug-resistant tuberculosis was enrolled in treatment. Pipelines for new diagnostics, drugs, and vaccines are progressing, but slowly. Actions needed to accelerate progress towards global milestones and targets for reductions in the burden of tuberculosis disease set for 2020, 2025, 2030, and 2035 include closing coverage gaps in testing, reporting of cases, and overall access to health care, especially in countries that account for the largest share of the global gap; multisectoral efforts to reduce prevalence of major risk factors for infection and disease; and increased investment in research and development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Houben, R. M. G. J., & Dodd, P. J. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002152 · Cited by 2,054
Drivers of tuberculosis epidemics: The role of risk factors and social determinants
Lönnroth, K., Jaramillo, E., Williams, B. G., Dye, C., & Raviglione, M. (2009) · Social Science & Medicine · doi:10.1016/j.socscimed.2009.03.041 · Cited by 1,176
Self-citationUplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Self-citationTuberculosis control and elimination 2010–50: cure, care, and social development
Lönnroth, K., Castro, K. G., Chakaya, J. M., Chauhan, L. S., Floyd, K., Glaziou, P., & Raviglione, M. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60483-7 · Cited by 899
Self-citationGetahun, H., Matteelli, A., Abubakar, I., Aziz, M. A., Baddeley, A., Barreira, D., Den Boon, S., Borroto Gutierrez, S. M., Bruchfeld, J., Burhan, E., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01245-2015 · Cited by 596
Self-citationRoy, A., Eisenhut, M., Harris, R. J., Rodrigues, L. C., Sridhar, S., Habermann, S., Snell, L., Mangtani, P., Adetifa, I., Lalvani, A., et al. (2014) · BMJ · doi:10.1136/bmj.g4643 · Cited by 588
Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017601 · Cited by 583
Equity, social determinants and public health programmes
Mukhopadhyay, A. (2011) · The Indian Journal of Medical Research · Cited by 539
Stenberg, K., Hanssen, O., Edejer, T. T.-T., Bertram, M., Brindley, C., Meshreky, A., Rosen, J. E., Stover, J., Verboom, P., Sanders, R., et al. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30263-2 · Cited by 506
The Anatomy of Medical Research: US and International Comparisons
Moses, H., Matheson, D. H. M., Cairns-Smith, S., George, B. P., Palisch, C., & Dorsey, E. R. (2015) · JAMA · doi:10.1001/jama.2014.15939 · Cited by 446
Cited by
Wang, Y., Zhao, M., Liu, S., Guo, J., Lu, Y., Cheng, J., & Liu, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03127-z · Cited by 267
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
Reid, M., Agbassi, Y. J. P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01379-x · Cited by 87
Self-citationPan, Z., Zhang, J., Bu, Q., He, H., Bai, L., Yang, J., Liu, Q., & Lyu, J. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s248875 · Cited by 29
Long‐term exposure to indoor air pollution and risk of tuberculosis
Patel, V., Foster, A., Salem, A., Kumar, A., Kumar, V., Biswas, B., Mirsaeidi, M., & Kumar, N. (2021) · Indoor Air · doi:10.1111/ina.12756 · Cited by 27
Zhang, L., Wang, S., Zhu, Y., & Yang, T. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s183039 · Cited by 16
Metadata
- Authors
- Floyd, K., Glaziou, P., Zumla, A., & Raviglione, M.
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 6
- Issue
- 4
- Pages
- 299-314
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W2794376461
- Cited by
- 440
- References
- 22
- FWCI
- 34.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. https://app.cochat.ai/papers/10.1016/s2213-2600(18)30057-2
- The paper
- Floyd, K., Glaziou, P., Zumla, A., & Raviglione, M. (2018). The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(18)30057-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.